Advertisement

Adnexal Carcinoma: Microcystic Adnexal Carcinoma and Sebaceous Carcinoma

  • Paul R. Massey
  • Anthony C. Soldano
  • Matthew C. Fox
Chapter

Abstract

Microcystic adnexal carcinoma (MAC) and sebaceous carcinoma (SC) are rare adnexal neoplasms. MAC most commonly presents as a poorly defined, firm, skin-colored papule, nodule, or plaque on the head and neck. Although locally destructive, MAC does not typically metastasize. Rates of misdiagnosis are high, due to incomplete, superficial sampling. Resection techniques with meticulous margin control, including Mohs micrographic surgery (MMS), are recommended in the management of MAC.

Sebaceous carcinoma, originating from holocrine sebocytes, is often found on the head and neck and is among the most common eyelid neoplasms. SC commonly presents as a firm, subcutaneous nodule with a yellow hue. SC may masquerade as other neoplastic and inflammatory entities, delaying diagnosis. Patients with SC must be screened for Muir-Torre syndrome, a hereditary cancer syndrome. Treatment for SC is surgical. SC has metastatic potential, most commonly to draining lymph node basins. Radiation and chemotherapy play a role in the management of metastatic disease.

Keywords

Microcystic adnexal carcinoma Sebaceous carcinoma Sebaceous neoplasm Desmoplastic trichoepithelioma Morpheaform basal cell carcinoma Muir-Torre Syndrome Sentinel lymph node biopsy Mohs micrographic surgery 

References

  1. 1.
    Goldstein DJ, Barr RJ, Santa Cruz DJ. Microcystic adnexal carcinoma: a distinct clinicopathologic entity. Cancer. 1982;50(3):566–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Pujol RM, LeBoit PE, Su WP. Microcystic adnexal carcinoma with extensive sebaceous differentiation. Am J Dermatopathol. 1997;19(4):358–62.PubMedCrossRefGoogle Scholar
  3. 3.
    Nickoloff BJ, Fleischmann HE, Carmel J, Wood CC, Roth RJ. Microcystic adnexal carcinoma. Immunohistologic observations suggesting dual (pilar and eccrine) differentiation. Arch Dermatol. 1986;122(3):290–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Boos MD, Elenitsas R, Seykora J, Lehrer MS, Miller CJ, Sobanko J. Benign subclinical syringomatous proliferations adjacent to a microcystic adnexal carcinoma: a tumor mimic with significant patient implications. Am J Dermatopathol. 2014;36(2):174–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Cardoso JC, Calonje E. Malignant sweat gland tumours: an update. Histopathology. 2015;67(5):589–606.PubMedCrossRefGoogle Scholar
  6. 6.
    Chiller K, Passaro D, Scheuller M, Singer M, McCalmont T, Grekin RC. Microcystic adnexal carcinoma: forty-eight cases, their treatment, and their outcome. Arch Dermatol. 2000;136(11):1355–9.PubMedGoogle Scholar
  7. 7.
    Yu JB, Blitzblau RC, Patel SC, Decker RH, Wilson LD. Surveillance, Epidemiology, and End Results (SEER) database analysis of microcystic adnexal carcinoma (sclerosing sweat duct carcinoma) of the skin. Am J Clin Oncol. 2010;33(2):125–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Diamantis SA, Marks VJ. Mohs micrographic surgery in the treatment of microcystic adnexal carcinoma. Dermatol Clin. 2011;29(2):185–90. viii.PubMedCrossRefGoogle Scholar
  9. 9.
    Fu T, Clark FL, Lorenz HP, Bruckner AL. Congenital microcystic adnexal carcinoma. Arch Dermatol. 2011;147(2):256–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Peterson CM, Ratz JL, Sangueza OP. Microcystic adnexal carcinoma: first reported case in an African American man. J Am Acad Dermatol. 2001;45(2):283–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Nadiminti H, Nadiminti U, Washington C. Microcystic adnexal carcinoma in African-Americans. Dermatol Surg. 2007;33(11):1384–7.PubMedGoogle Scholar
  12. 12.
    Ohtsuka H, Nagamatsu S. Microcystic adnexal carcinoma: review of 51 Japanese patients. Dermatology. 2002;204(3):190–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Chen J, Yang S, Liao T, Deng W, Li W. Microcystic adnexal carcinoma in a non-Caucasian patient: a case report and review of the literature. Oncol Lett. 2016;11(4):2471–4.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Tolkachjov SN, Schmitt AR, Muzic JG, Weaver AL, Baum CL. Incidence and clinical features of rare cutaneous malignancies in Olmsted County, Minnesota, 2000 to 2010. Dermatol Surg. 2017;43(1):116–24.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Wick MR, Cooper PH, Swanson PE, Kaye VN, Sun TT. Microcystic adnexal carcinoma. An immunohistochemical comparison with other cutaneous appendage tumors. Arch Dermatol. 1990;126(2):189–94.PubMedCrossRefGoogle Scholar
  16. 16.
    Avraham JB, Villines D, Maker VK, August C, Maker AV. Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: risk factors and trends in outcomes. J Surg Oncol. 2013;108(1):57–62.PubMedCrossRefGoogle Scholar
  17. 17.
    LeBoit PE, Sexton M. Microcystic adnexal carcinoma of the skin. A reappraisal of the differentiation and differential diagnosis of an underrecognized neoplasm. J Am Acad Dermatol. 1993;29(4):609–18.PubMedCrossRefGoogle Scholar
  18. 18.
    Snow S, Madjar DD, Hardy S, Bentz M, Lucarelli MJ, Bechard R, et al. Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg. 2001;27(4):401–8.PubMedGoogle Scholar
  19. 19.
    Carroll P, Goldstein GD, Brown CW. Metastatic microcystic adnexal carcinoma in an immunocompromised patient. Dermatol Surg. 2000;26(6):531–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Smith KJ, Williams J, Corbett D, Skelton H. Microcystic adnexal carcinoma: an immunohistochemical study including markers of proliferation and apoptosis. Am J Surg Pathol. 2001;25(4):464–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Wohlfahrt C, Ternesten A, Sahlin P, Islam Q, Stenman G. Cytogenetic and fluorescence in situ hybridization analyses of a microcystic adnexal carcinoma with del(6)(q23q25). Cancer Genet Cytogenet. 1997;98(2):106–10.PubMedCrossRefGoogle Scholar
  22. 22.
    Kishi M, Nakamura M, Nishimine M, Ishida E, Shimada K, Kirita T, et al. Loss of heterozygosity on chromosome 6q correlates with decreased thrombospondin-2 expression in human salivary gland carcinomas. Cancer Sci. 2003;94(6):530–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Dupré A, Carrère S, Bonafé JL, Christol B, Lassère J, Touron P. Eruptive generalized syringomas, milium and atrophoderma vermiculata. Nicolau and Balus' syndrome (author's transl). Dermatologica. 1981;162(4):281–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Ranasinghe AR, Batchelor J, Ha T. Nicolau Balus syndrome with microcystic adnexal carcinoma. J Am Acad Dermatol. 2013;68(4):AB56.Google Scholar
  25. 25.
    Schaller J, Rytina E, Rütten A, Hendricks C, Ha T, Requena L. Sweat duct proliferation associated with aggregates of elastic tissue and atrophodermia vermiculata: a simulator of microcystic adnexal carcinoma. Report of two cases. J Cutan Pathol. 2010;37(9):1002–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Page RN, Hanggi MC, King R, Googe PB. Multiple microcystic adnexal carcinomas. Cutis. 2007;79(4):299–303.PubMedGoogle Scholar
  27. 27.
    Leibovitch I, Huilgol SC, Selva D, Lun K, Richards S, Paver R. Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52(2):295–300.PubMedCrossRefGoogle Scholar
  28. 28.
    Connolly KL, Nehal KS, Disa JJ. Evidence-based medicine: cutaneous facial malignancies: nonmelanoma skin cancer. Plast Reconstr Surg. 2017;139(1):181e–90e.PubMedCrossRefGoogle Scholar
  29. 29.
    Friedman PM, Friedman RH, Jiang SB, Nouri K, Amonette R, Robins P. Microcystic adnexal carcinoma: collaborative series review and update. J Am Acad Dermatol. 1999;41(2 Pt 1):225–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Yugueros P, Kane WJ, Goellner JR. Sweat gland carcinoma: a clinicopathologic analysis of an expanded series in a single institution. Plast Reconstr Surg. 1998;102(3):705–10.PubMedCrossRefGoogle Scholar
  31. 31.
    Obaidat NA, Alsaad KO, Ghazarian D. Skin adnexal neoplasms--part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007;60(2):145–59.PubMedCrossRefGoogle Scholar
  32. 32.
    Sellheyer K, Nelson P, Kutzner H, Patel RM. The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers. J Cutan Pathol. 2013;40(4):363–70.PubMedCrossRefGoogle Scholar
  33. 33.
    Fu JM, McCalmont T, Yu SS. Adenosquamous carcinoma of the skin: a case series. Arch Dermatol. 2009;145(10):1152–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Frouin E, Vignon-Pennamen MD, Balme B, Cavelier-Balloy B, Zimmermann U, Ortonne N, et al. Anatomoclinical study of 30 cases of sclerosing sweat duct carcinomas (microcystic adnexal carcinoma, syringomatous carcinoma and squamoid eccrine ductal carcinoma). J Eur Acad Dermatol Venereol. 2015;29(10):1978–94.PubMedCrossRefGoogle Scholar
  35. 35.
    Sebastien TS, Nelson BR, Lowe L, Baker S, Johnson TM. Microcystic adnexal carcinoma. J Am Acad Dermatol. 1993;29(5 Pt 2):840–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Crowson AN, Magro CM, Mihm MC. Malignant adnexal neoplasms. Mod Pathol. 2006;19(Suppl 2):S93–S126.PubMedCrossRefGoogle Scholar
  37. 37.
    Urso C, Bondi R, Paglierani M, Salvadori A, Anichini C, Giannini A. Carcinomas of sweat glands: report of 60 cases. Arch Pathol Lab Med. 2001;125(4):498–505.PubMedGoogle Scholar
  38. 38.
    Merritt BG, Snow SN, Longley BJ. Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery. Cutis. 2010;85(5):254–8.PubMedGoogle Scholar
  39. 39.
    Costache M, Bresch M, Böer A. Desmoplastic trichoepithelioma versus morphoeic basal cell carcinoma: a critical reappraisal of histomorphological and immunohistochemical criteria for differentiation. Histopathology. 2008;52(7):865–76.PubMedCrossRefGoogle Scholar
  40. 40.
    Shinohara R, Ansai S, Ogita A, Matsuda H, Saeki H, Tanaka M. Dermoscopic findings of microcystic adnexal carcinoma. Eur J Dermatol. 2015;25(5):516–8.PubMedGoogle Scholar
  41. 41.
    Hoang MP, Dresser KA, Kapur P, High WA, Mahalingam M. Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol. 2008;21(2):178–85.PubMedCrossRefGoogle Scholar
  42. 42.
    Nagatsuka H, Rivera RS, Gunduz M, Siar CH, Tamamura R, Mizukawa N, et al. Microcystic adnexal carcinoma with mandibular bone marrow involvement: a case report with immunohistochemistry. Am J Dermatopathol. 2006;28(6):518–22.PubMedCrossRefGoogle Scholar
  43. 43.
    Krahl D, Sellheyer K. Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol. 2007;34(10):782–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Abesamis-Cubillan E, El-Shabrawi-Caelen L, PE LB. Merked cells and sclerosing epithelial neoplasms. Am J Dermatopathol. 2000;22(4):311–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Patrizi A, Neri I, Marzaduri S, Varotti E, Passarini B. Syringoma: a review of twenty-nine cases. Acta Derm Venereol. 1998;78(6):460–2.PubMedCrossRefGoogle Scholar
  46. 46.
    Salasche SJ, Amonette RA. Morpheaform basal-cell epitheliomas. A study of subclinical extensions in a series of 51 cases. J Dermatol Surg Oncol. 1981;7(5):387–94.PubMedCrossRefGoogle Scholar
  47. 47.
    Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344(13):975–83.PubMedCrossRefGoogle Scholar
  48. 48.
    Wang Q, Ghimire D, Wang J, Luo S, Li Z, Wang H, et al. Desmoplastic trichoepithelioma: a clinicopathological study of three cases and a review of the literature. Oncol Lett. 2015;10(4):2468–76.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Popadić M. Dermoscopy of aggressive basal cell carcinomas. Indian J Dermatol Venereol Leprol. 2015;81(6):608–10.PubMedCrossRefGoogle Scholar
  50. 50.
    Tawfik AM, Kreft A, Wagner W, Vogl TJ. MRI of a microcystic adnexal carcinoma of the skin mimicking a fibrous tumour: case report and literature review. Br J Radiol. 2011;84(1002):e114–7.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Gomez-Maestra MJ, España-Gregori E, Aviñó-Martinez JA, Mancheño-Franch N, Peña S. Brainstem and cavernous sinus metastases arising from a microcystic adnexal carcinoma of the eyebrow by perineural spreading. Can J Ophthalmol. 2009;44(3):e17–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Beltramini GA, Baj A, Moneghini L, Poli T, Combi VA, Giannì AB. Microcystic adnexal carcinoma of the centrofacial region: a case report. Acta Otorhinolaryngol Ital. 2010;30(4):213.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Cooper PH, Mills SE, Leonard DD, Santa Cruz DJ, Headington JT, Barr RJ, et al. Sclerosing sweat duct (syringomatous) carcinoma. Am J Surg Pathol. 1985;9(6):422–33.PubMedCrossRefGoogle Scholar
  54. 54.
    Abbate M, Zeitouni NC, Seyler M, Hicks W, Loree T, Cheney RT. Clinical course, risk factors, and treatment of microcystic adnexal carcinoma: a short series report. Dermatol Surg. 2003;29(10):1035–8.PubMedGoogle Scholar
  55. 55.
    Palamaras I, McKenna JD, Robson A, Barlow RJ. Microcystic adnexal carcinoma: a case series treated with mohs micrographic surgery and identification of patients in whom paraffin sections may be preferable. Dermatol Surg. 2010;36(4):446–52.PubMedCrossRefGoogle Scholar
  56. 56.
    Lopez M, Cole EL. Microcystic adnexal carcinoma: reconstruction of a large centrofacial defect. Plast Reconstr Surg Glob Open. 2014;2(11):e254.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Eisen DB, Zloty D. Microcystic adnexal carcinoma involving a large portion of the face: when is surgery not reasonable? Dermatol Surg. 2005;31(11 Pt 1):1472–7. discussion 8.PubMedGoogle Scholar
  58. 58.
    Rotter N, Wagner H, Fuchshuber S, Issing WJ. Cervical metastases of microcystic adnexal carcinoma in an otherwise healthy woman. Eur Arch Otorhinolaryngol. 2003;260(5):254–7.PubMedGoogle Scholar
  59. 59.
    Green M, Mitchum M, Marquart J, Bowden LP, Bingham J. Microcystic adnexal carcinoma in the axilla of an 18-year-old woman. Pediatr Dermatol. 2014;31(6):e145–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Ban M, Sugie S, Kamiya H, Kitajima Y. Microcystic adnexal carcinoma with lymph node metastasis. Dermatology. 2003;207(4):395–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Gulmen S, Pullon PA. Sweat gland carcinoma of the lips. Oral Surg Oral Med Oral Pathol. 1976;41(5):643–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Stein JM, Ormsby A, Esclamado R, Bailin P. The effect of radiation therapy on microcystic adnexal carcinoma: a case report. Head Neck. 2003;25(3):251–4.PubMedCrossRefGoogle Scholar
  63. 63.
    Baxi S, Deb S, Weedon D, Baumann K, Poulsen M. Microcystic adnexal carcinoma of the skin: the role of adjuvant radiotherapy. J Med Imaging Radiat Oncol. 2010;54(5):477–82.PubMedCrossRefGoogle Scholar
  64. 64.
    Yuh WT, Engelken JD, Whitaker DC, Dolan KD. Bone marrow invasion of microcystic adnexal carcinoma. Ann Otol Rhinol Laryngol. 1991;100(7):601–3.PubMedCrossRefGoogle Scholar
  65. 65.
    Shields JA, Demirci H, Marr BP, Eagle RC, Shields CL. Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol. 2005;50(2):103–22.PubMedCrossRefGoogle Scholar
  66. 66.
    Tripathi R, Chen Z, Li L, Bordeaux JS. Incidence and survival of sebaceous carcinoma in the United States. J Am Acad Dermatol. 2016;75(6):1210–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Doxanas MT, Green WR. Sebaceous gland carcinoma. Review of 40 cases. Arch Ophthalmol. 1984;102(2):245–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Kyllo RL, Brady KL, Hurst EA. Sebaceous carcinoma: review of the literature. Dermatol Surg. 2015;41(1):1–15.PubMedCrossRefGoogle Scholar
  69. 69.
    Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol. 2005;6(12):980–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Dores GM, Curtis RE, Toro JR, Devesa SS, Fraumeni JF. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer. 2008;113(12):3372–81.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Nelson BR, Hamlet KR, Gillard M, Railan D, Johnson TM. Sebaceous carcinoma. J Am Acad Dermatol. 1995;33(1):1–15. quiz 6-8.PubMedCrossRefGoogle Scholar
  72. 72.
    Natarajan K, Rai R, Pillai SB. Extra ocular sebaceous carcinoma: a rare case report. Indian Dermatol Online J. 2011;2(2):91–3.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Brady KL, Hurst EA. Sebaceous carcinoma treated with Mohs micrographic surgery. Dermatol Surg. 2017;43(2):281–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Slutsky JB, Jones EC. Periocular cutaneous malignancies: a review of the literature. Dermatol Surg. 2012;38(4):552–69.PubMedCrossRefGoogle Scholar
  75. 75.
    Pereira PR, Odashiro AN, Rodrigues-Reyes AA, Correa ZM, de Souza Filho JP, Burnier MN. Histopathological review of sebaceous carcinoma of the eyelid. J Cutan Pathol. 2005;32(7):496–501.PubMedCrossRefGoogle Scholar
  76. 76.
    Reifler DM, Hornblass A. Squamous cell carcinoma of the eyelid. Surv Ophthalmol. 1986;30(6):349–65.PubMedCrossRefGoogle Scholar
  77. 77.
    Nemoto Y, Arita R, Mizota A, Sasajima Y. Differentiation between chalazion and sebaceous carcinoma by noninvasive meibography. Clin Ophthalmol. 2014;8:1869–75.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Coates D, Bowling J, Haskett M. Dermoscopic features of extraocular sebaceous carcinoma. Australas J Dermatol. 2011;52(3):212–3.PubMedCrossRefGoogle Scholar
  79. 79.
    Rao NA, Hidayat AA, McLean IW, Zimmerman LE. Sebaceous carcinomas of the ocular adnexa: a clinicopathologic study of 104 cases, with five-year follow-up data. Hum Pathol. 1982;13(2):113–22.PubMedCrossRefGoogle Scholar
  80. 80.
    Ni C, Searl SS, Kuo PK, Chu FR, Chong CS, Albert DM. Sebaceous cell carcinomas of the ocular adnexa. Int Ophthalmol Clin. 1982;22(1):23–61.PubMedCrossRefGoogle Scholar
  81. 81.
    Yin VT, Merritt HA, Sniegowski M, Esmaeli B. Eyelid and ocular surface carcinoma: diagnosis and management. Clin Dermatol. 2015;33(2):159–69.PubMedCrossRefGoogle Scholar
  82. 82.
    Wali UK, Al-Mujaini A. Sebaceous gland carcinoma of the eyelid. Oman J Ophthalmol. 2010;3(3):117–21.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Cook BE, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology. 1999;106(4):746–50.PubMedCrossRefGoogle Scholar
  84. 84.
    Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115(1):158–65.PubMedCrossRefGoogle Scholar
  85. 85.
    Blake PW, Bradford PT, Devesa SS, Toro JR. Cutaneous appendageal carcinoma incidence and survival patterns in the United States: a population-based study. Arch Dermatol. 2010;146(6):625–32.PubMedCrossRefGoogle Scholar
  86. 86.
    Wolfe JT, Yeatts RP, Wick MR, Campbell RJ, Waller RR. Sebaceous carcinoma of the eyelid. Errors in clinical and pathologic diagnosis. Am J Surg Pathol. 1984;8(8):597–606.PubMedCrossRefGoogle Scholar
  87. 87.
    Dowd MB, Kumar RJ, Sharma R, Murali R. Diagnosis and management of sebaceous carcinoma: an Australian experience. ANZ J Surg. 2008;78(3):158–63.PubMedCrossRefGoogle Scholar
  88. 88.
    Kass LG, Hornblass A. Sebaceous carcinoma of the ocular adnexa. Surv Ophthalmol. 1989;33(6):477–90.PubMedCrossRefGoogle Scholar
  89. 89.
    Sung D, Kaltreider SA, Gonzalez-Fernandez F. Early onset sebaceous carcinoma. Diagn Pathol. 2011;6:81.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Kivelä T, Asko-Seljavaara S, Pihkala U, Hovi L, Heikkonen J. Sebaceous carcinoma of the eyelid associated with retinoblastoma. Ophthalmology. 2001;108(6):1124–8.PubMedCrossRefGoogle Scholar
  91. 91.
    Abdi U, Tyagi N, Maheshwari V, Gogi R, Tyagi SP. Tumours of eyelid: a clinicopathologic study. J Indian Med Assoc. 1996;94(11):405. -9, 16, 18.PubMedGoogle Scholar
  92. 92.
    Kiyosaki K, Nakada C, Hijiya N, Tsukamoto Y, Matsuura K, Nakatsuka K, et al. Analysis of p53 mutations and the expression of p53 and p21WAF1/CIP1 protein in 15 cases of sebaceous carcinoma of the eyelid. Invest Ophthalmol Vis Sci. 2010;51(1):7–11.PubMedCrossRefGoogle Scholar
  93. 93.
    Hussain RM, Matthews JL, Dubovy SR, Thompson JM, Wang G. UV-independent p53 mutations in sebaceous carcinoma of the eyelid. Ophthal Plast Reconstr Surg. 2014;30(5):392–5.PubMedCrossRefGoogle Scholar
  94. 94.
    Gonzalez-Fernandez F, Kaltreider SA, Patnaik BD, Retief JD, Bao Y, Newman S, et al. Sebaceous carcinoma. Tumor progression through mutational inactivation of p53. Ophthalmology. 1998;105(3):497–506.PubMedCrossRefGoogle Scholar
  95. 95.
    Shalin SC, Sakharpe A, Lyle S, Lev D, Calonje E, Lazar AJ. p53 staining correlates with tumor type and location in sebaceous neoplasms. Am J Dermatopathol. 2012;34(2):129–35. quiz 36-8.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Hayashi N, Furihata M, Ohtsuki Y, Ueno H. Search for accumulation of p53 protein and detection of human papillomavirus genomes in sebaceous gland carcinoma of the eyelid. Virchows Arch. 1994;424(5):503–9.PubMedCrossRefGoogle Scholar
  97. 97.
    Cho KJ, Khang SK, Koh JS, Chung JH, Lee SS. Sebaceous carcinoma of the eyelids: frequent expression of c-erbB-2 oncoprotein. J Korean Med Sci. 2000;15(5):545–50.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Stagner AM, Afrogheh AH, Jakobiec FA, Iacob CE, Grossniklaus HE, Deshpande V, et al. p16 expression is not a surrogate marker for high-risk human papillomavirus infection in periocular sebaceous carcinoma. Am J Ophthalmol. 2016;170:168–75.PubMedCrossRefGoogle Scholar
  99. 99.
    Kwon MJ, Shin HS, Nam ES, Cho SJ, Lee MJ, Lee S, et al. Comparison of HER2 gene amplification and KRAS alteration in eyelid sebaceous carcinomas with that in other eyelid tumors. Pathol Res Pract. 2015;211(5):349–55.PubMedCrossRefGoogle Scholar
  100. 100.
    Liau JY, Liao SL, Hsiao CH, Lin MC, Chang HC, Kuo KT. Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age. Hum Pathol. 2014;45(3):533–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Landis MN, Davis CL, Bellus GA, Wolverton SE. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy. J Am Acad Dermatol. 2011;65(5):1054–8.e1.PubMedCrossRefGoogle Scholar
  102. 102.
    Hoss E, Nelson SA, Sharma A. Sebaceous carcinoma in solid organ transplant recipients. Int J Dermatol. 2017;56:746.PubMedCrossRefGoogle Scholar
  103. 103.
    Yen MT, Tse DT. Sebaceous cell carcinoma of the eyelid and the human immunodeficiency virus. Ophthal Plast Reconstr Surg. 2000;16(3):206–10.PubMedCrossRefGoogle Scholar
  104. 104.
    Rumelt S, Hogan NR, Rubin PA, Jakobiec FA. Four-eyelid sebaceous cell carcinoma following irradiation. Arch Ophthalmol. 1998;116(12):1670–2.PubMedCrossRefGoogle Scholar
  105. 105.
    Hood IC, Qizilbash AH, Salama SS, Young JE, Archibald SD. Sebaceous carcinoma of the face following irradiation. Am J Dermatopathol. 1986;8(6):505–8.PubMedCrossRefGoogle Scholar
  106. 106.
    Schlernitzauer DA, Font RL. Sebaceous gland carcinoma of the eyelid. Arch Ophthalmol. 1976;94(9):1523–5.PubMedCrossRefGoogle Scholar
  107. 107.
    Izumi M, Tang X, Chiu CS, Nagai T, Matsubayashi J, Iwaya K, et al. Ten cases of sebaceous carcinoma arising in nevus sebaceus. J Dermatol. 2008;35(11):704–11.PubMedCrossRefGoogle Scholar
  108. 108.
    Wenzel CT, Halperin EC, Fisher SR. Second malignant neoplasms of the head and neck in survivors of retinoblastoma. Ear Nose Throat J. 2001;80(2):106, 9–12.PubMedGoogle Scholar
  109. 109.
    Lemos LB, Santa Cruz DJ, Baba N. Sebaceous carcinoma of the eyelid following radiation therapy. Am J Surg Pathol. 1978;2(3):305–11.PubMedCrossRefGoogle Scholar
  110. 110.
    Howrey RP, Lipham WJ, Schultz WH, Buckley EG, Dutton JJ, Klintworth GK, et al. Sebaceous gland carcinoma: a subtle second malignancy following radiation therapy in patients with bilateral retinoblastoma. Cancer. 1998;83(4):767–71.PubMedCrossRefGoogle Scholar
  111. 111.
    John AM, Schwartz RA. Muir-Torre syndrome (MTS): an update and approach to diagnosis and management. J Am Acad Dermatol. 2016;74(3):558–66.PubMedCrossRefGoogle Scholar
  112. 112.
    Mahalingam M. MSH6, past and present and Muir-Torre syndrome-connecting the dots. Am J Dermatopathol. 2017;39(4):239–49.PubMedCrossRefGoogle Scholar
  113. 113.
    Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol. 1995;33(1):90–104.PubMedCrossRefGoogle Scholar
  114. 114.
    Jessup CJ, Redston M, Tilton E, Reimann JD. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome. Hum Pathol. 2016;49:1–9.PubMedCrossRefGoogle Scholar
  115. 115.
    Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res. 2012;18(6):1506–12.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Cohen PR, Kohn SR, Kurzrock R. Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med. 1991;90(5):606–13.PubMedCrossRefGoogle Scholar
  117. 117.
    Lazar AJ, Lyle S, Calonje E. Sebaceous neoplasia and Torre-Muir syndrome. Curr Diagn Pathol. 2007;13(4):301–19.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Bhaijee F, Brown AS. Muir-Torre syndrome. Arch Pathol Lab Med. 2014;138(12):1685–9.PubMedCrossRefGoogle Scholar
  119. 119.
    Grob A, Feser C, Grekin S. Muir-torre syndrome:a case associated with an infrequent gene mutation. J Clin Aesthet Dermatol. 2016;9(1):56–9.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Singh RS, Grayson W, Redston M, Diwan AH, Warneke CL, McKee PH, et al. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol. 2008;32(6):936–42.PubMedCrossRefGoogle Scholar
  121. 121.
    Zürcher M, Hintschich CR, Garner A, Bunce C, Collin JR. Sebaceous carcinoma of the eyelid: a clinicopathological study. Br J Ophthalmol. 1998;82(9):1049–55.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Demirci H, Nelson CC, Shields CL, Eagle RC, Shields JA. Eyelid sebaceous carcinoma associated with Muir-Torre syndrome in two cases. Ophthal Plast Reconstr Surg. 2007;23(1):77–9.PubMedCrossRefGoogle Scholar
  123. 123.
    Wick MR, Goellner JR, Wolfe JT, Su WP. Adnexal carcinomas of the skin. II. Extraocular sebaceous carcinomas. Cancer. 1985;56(5):1163–72.PubMedCrossRefGoogle Scholar
  124. 124.
    Hou JL, Killian JM, Baum CL, Otley CC, Roenigk RK, Arpey CJ, et al. Characteristics of sebaceous carcinoma and early outcomes of treatment using Mohs micrographic surgery versus wide local excision: an update of the Mayo Clinic experience over the past 2 decades. Dermatol Surg. 2014;40(3):241–6.PubMedCrossRefGoogle Scholar
  125. 125.
    Cook BE, Bartley GB. Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update. Ophthalmology. 2001;108(11):2088–98; quiz 99–100, 121.PubMedCrossRefGoogle Scholar
  126. 126.
    Shields JA, Demirci H, Marr BP, Eagle RC, Shields CL. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology. 2004;111(12):2151–7.PubMedCrossRefGoogle Scholar
  127. 127.
    Wang JK, Liao SL, Jou JR, Lai PC, Kao SC, Hou PK, et al. Malignant eyelid tumours in Taiwan. Eye (Lond). 2003;17(2):216–20.CrossRefGoogle Scholar
  128. 128.
    Husain A, Blumenschein G, Esmaeli B. Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol. 2008;47(3):276–9.PubMedCrossRefGoogle Scholar
  129. 129.
    Muqit MM, Roberts F, Lee WR, Kemp E. Improved survival rates in sebaceous carcinoma of the eyelid. Eye (Lond). 2004;18(1):49–53.CrossRefGoogle Scholar
  130. 130.
    Boniuk M, Zimmerman LE. Sebaceous carcinoma of the eyelid, eyebrow, caruncle, and orbit. Trans Am Acad Ophthalmol Otolaryngol. 1968;72(4):619–42.PubMedGoogle Scholar
  131. 131.
    Sawyer AR, McGoldrick RB, Mackey S, Powell B, Pohl M. Should extraocular sebaceous carcinoma be investigated using sentinel node biopsy? Dermatol Surg. 2009;35(4):704–8.PubMedCrossRefGoogle Scholar
  132. 132.
    Rulon DB, Helwig EB. Cutaneous sebaceous neoplasms. Cancer. 1974;33(1):82–102.PubMedCrossRefGoogle Scholar
  133. 133.
    Chang AY, Miller CJ, Elenitsas R, Newman JG, Sobanko JF. Management considerations in extraocular sebaceous carcinoma. Dermatol Surg. 2016;42(Suppl 1):S57–65.PubMedCrossRefGoogle Scholar
  134. 134.
    Shalin SC, Lyle S, Calonje E, Lazar AJ. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. Histopathology. 2010;56(1):133–47.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Font R. Eyelids and lacrimal drainage system. In: Spencer WH, editor. Ophthalmic pathology: an atlas and textbook. 3rd ed. Philadelphia: WB Saunders; 1986. p. 2169–214.Google Scholar
  136. 136.
    Pfeiffer ML, Yin VT, Myers J, Esmaeli B. Regional nodal recurrence of sebaceous carcinoma of the caruncle 11 years after primary tumor resection. JAMA Ophthalmol. 2013;131(8):1091–2.PubMedCrossRefGoogle Scholar
  137. 137.
    Kohler S, Rouse RV, Smoller BR. The differential diagnosis of pagetoid cells in the epidermis. Mod Pathol. 1998;11(1):79–92.PubMedGoogle Scholar
  138. 138.
    Sramek B, Lisle A, Loy T. Immunohistochemistry in ocular carcinomas. J Cutan Pathol. 2008;35(7):641–6.PubMedCrossRefGoogle Scholar
  139. 139.
    Beer TW, Shepherd P, Theaker JM. Ber EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin. Histopathology. 2000;37(3):218–23.PubMedCrossRefGoogle Scholar
  140. 140.
    Ansai SI. Topics in histopathology of sweat gland and sebaceous neoplasms. J Dermatol. 2017;44(3):315–26.PubMedCrossRefGoogle Scholar
  141. 141.
    Rajan Kd A, Burris C, Iliff N, Grant M, Eshleman JR, Eberhart CG. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma. Am J Ophthalmol. 2014;157(3):640–7.e1–2.PubMedCrossRefGoogle Scholar
  142. 142.
    Buitrago W, Joseph AK. Sebaceous carcinoma: the great masquerader: emerging concepts in diagnosis and treatment. Dermatol Ther. 2008;21(6):459–66.PubMedCrossRefGoogle Scholar
  143. 143.
    Esmaeli B, Nasser QJ, Cruz H, Fellman M, Warneke CL, Ivan D. American joint committee on cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival. Ophthalmology. 2012;119(5):1078–82.PubMedCrossRefGoogle Scholar
  144. 144.
    American Joint Committee on Cancer. New York, NY: Springer; 2010.Google Scholar
  145. 145.
    Reina RS, Parry E. Aggressive extraocular sebaceous carcinoma in a 52-year-old man. Dermatol Surg. 2006;32(10):1283–6.PubMedGoogle Scholar
  146. 146.
    Orcurto A, Gay BE, Sozzi WJ, Gilliet M, Leyvraz S. Long-term remission of an aggressive sebaceous carcinoma following chemotherapy. Case Rep Dermatol. 2014;6(1):80–4.PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    Herceg D, Kusacić-Kuna S, Dotlić S, Petrović R, Bracić I, Horvatić Herceg G, et al. F-18 FDG PET evaluation of a rapidly growing extraocular sebaceous carcinoma. Clin Nucl Med. 2009;34(11):798–801.PubMedCrossRefGoogle Scholar
  148. 148.
    Baek CH, Chung MK, Jeong HS, Son YI, Choi J, Kim YD, et al. The clinical usefulness of (18)F-FDG PET/CT for the evaluation of lymph node metastasis in periorbital malignancies. Korean J Radiol. 2009;10(1):1–7.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Ginsberg J. Present status of meibomian gland carcinoma. Arch Ophthalmol. 1965;73:271–7.PubMedCrossRefGoogle Scholar
  150. 150.
    Erovic BM, Goldstein DP, Kim D, Al Habeeb A, Waldron J, Ghazarian D, et al. Sebaceous gland carcinoma of the head and neck: the Princess Margaret Hospital experience. Head Neck. 2013;35(3):316–20.PubMedCrossRefGoogle Scholar
  151. 151.
    Bailet JW, Zimmerman MC, Arnstein DP, Wollman JS, Mickel RA. Sebaceous carcinoma of the head and neck. Case report and literature review. Arch Otolaryngol Head Neck Surg. 1992;118(11):1245–9.PubMedCrossRefGoogle Scholar
  152. 152.
    Tryggvason G, Bayon R, Pagedar NA. Epidemiology of sebaceous carcinoma of the head and neck: implications for lymph node management. Head Neck. 2012;34(12):1765–8.PubMedCrossRefGoogle Scholar
  153. 153.
    Ho VH, Ross MI, Prieto VG, Khaleeq A, Kim S, Esmaeli B. Sentinel lymph node biopsy for sebaceous cell carcinoma and melanoma of the ocular adnexa. Arch Otolaryngol Head Neck Surg. 2007;133(8):820–6.PubMedCrossRefGoogle Scholar
  154. 154.
    Nijhawan N, Ross MI, Diba R, Ahmadi MA, Esmaeli B. Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies at a cancer center. Ophthal Plast Reconstr Surg. 2004;20(4):291–5.PubMedCrossRefGoogle Scholar
  155. 155.
    Savar A, Oellers P, Myers J, Prieto VG, Torres-Cabala C, Frank SJ, et al. Positive sentinel node in sebaceous carcinoma of the eyelid. Ophthal Plast Reconstr Surg. 2011;27(1):e4–6.PubMedCrossRefGoogle Scholar
  156. 156.
    Harrington CR, Egbert BM, Swetter SM. Extraocular sebaceous carcinoma in a patient with Muir-Torre syndrome. Dermatol Surg. 2004;30(5):817–9.PubMedGoogle Scholar
  157. 157.
    Pfeiffer ML, Savar A, Esmaeli B. Sentinel lymph node biopsy for eyelid and conjunctival tumors: what have we learned in the past decade? Ophthal Plast Reconstr Surg. 2013;29(1):57–62.PubMedCrossRefGoogle Scholar
  158. 158.
    Spencer JM, Nossa R, Tse DT, Sequeira M. Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol. 2001;44(6):1004–9.PubMedCrossRefGoogle Scholar
  159. 159.
    Grigoryan KV, Leithauser L, Gloster HM. Aggressive extraocular sebaceous carcinoma recurring after mohs micrographic surgery. Case Rep Oncol Med. 2015;2015:534176.PubMedPubMedCentralGoogle Scholar
  160. 160.
    Callahan EF, Appert DL, Roenigk RK, Bartley GB. Sebaceous carcinoma of the eyelid: a review of 14 cases. Dermatol Surg. 2004;30(8):1164–8.PubMedGoogle Scholar
  161. 161.
    Dogru M, Matsuo H, Inoue M, Okubo K, Yamamoto M. Management of eyelid sebaceous carcinomas. Ophthalmologica. 1997;211(1):40–3.PubMedCrossRefGoogle Scholar
  162. 162.
    Snow SN, Larson PO, Lucarelli MJ, Lemke BN, Madjar DD. Sebaceous carcinoma of the eyelids treated by mohs micrographic surgery: report of nine cases with review of the literature. Dermatol Surg. 2002;28(7):623–31.PubMedGoogle Scholar
  163. 163.
    Cavanagh HD, Green WR, Goldberg HK. Multicentric sebaceous adenocarcinoma of the meibomian gland. Am J Ophthalmol. 1974;77(3):326–32.PubMedCrossRefGoogle Scholar
  164. 164.
    Nunery WR, Welsh MG, McCord CD. Recurrence of sebaceous carcinoma of the eyelid after radiation therapy. Am J Ophthalmol. 1983;96(1):10–5.PubMedCrossRefGoogle Scholar
  165. 165.
    Hendley RL, Rieser JC, Cavanagh HD, Bodner BI, Waring GO. Primary radiation therapy for meibomian gland carcinoma. Am J Ophthalmol. 1979;87(2):206–9.PubMedCrossRefGoogle Scholar
  166. 166.
    Hata M, Koike I, Omura M, Maegawa J, Ogino I, Inoue T. Noninvasive and curative radiation therapy for sebaceous carcinoma of the eyelid. Int J Radiat Oncol Biol Phys. 2012;82(2):605–11.PubMedCrossRefGoogle Scholar
  167. 167.
    Yen MT, Tse DT, Wu X, Wolfson AH. Radiation therapy for local control of eyelid sebaceous cell carcinoma: report of two cases and review of the literature. Ophthal Plast Reconstr Surg. 2000;16(3):211–5.PubMedCrossRefGoogle Scholar
  168. 168.
    Pardo FS, Wang CC, Albert D, Stracher MA. Sebaceous carcinoma of the ocular adnexa: radiotherapeutic management. Int J Radiat Oncol Biol Phys. 1989;17(3):643–7.PubMedCrossRefGoogle Scholar
  169. 169.
    Jung YH, Woo IS, Kim MY, Han CW, Rha EY. Palliative 5-fluorouracil and cisplatin chemotherapy in recurrent metastatic sebaceous carcinoma: case report and literature review. Asia Pac J Clin Oncol. 2016;12(1):e189–93.PubMedCrossRefGoogle Scholar
  170. 170.
    Murthy R, Honavar SG, Burman S, Vemuganti GK, Naik MN, Reddy VA. Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. Ophthal Plast Reconstr Surg. 2005;21(4):307–9.PubMedCrossRefGoogle Scholar
  171. 171.
    Priyadarshini O, Biswas G, Biswas S, Padhi R, Rath S. Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy. Ophthal Plast Reconstr Surg. 2010;26(5):366–8.PubMedCrossRefGoogle Scholar
  172. 172.
    Paschal BR, Bagley CS. Sebaceous land carcinoma of the eyelid: complete response to sequential combination chemotherapy. N C Med J. 1985;46(9):473–4.PubMedGoogle Scholar
  173. 173.
    el Nakadi B, Nouwynck C, Salhadin A. Combined therapeutic approach for extraorbital sebaceous carcinoma in a Torre's syndrome. Eur J Surg Oncol. 1995;21(3):321–2.PubMedCrossRefGoogle Scholar
  174. 174.
    De Leo A, Innocenzi D, Onesti MG, Potenza C, Toscani M, Scuderi N. Extraocular sebaceous carcinoma in Muir Torre Syndrome with unfavorable prognosis. Cancer Chemother Pharmacol. 2006;58(6):842–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Paul R. Massey
    • 1
  • Anthony C. Soldano
    • 1
  • Matthew C. Fox
    • 1
  1. 1.Division of DermatologyDell Medical School, University of Texas at AustinAustinUSA

Personalised recommendations